|
1
|
So JY, Ohm J, Lipkowitz S and Yang L:
Triple negative breast cancer (TNBC): Non-genetic tumor
heterogeneity and immune microenvironment: Emerging treatment
options. Pharmacol Ther. 237:1082532022. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zagami P and Carey LA: Triple negative
breast cancer: Pitfalls and progress. Npj Breast Cancer. 8:952022.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Almansour NM: Triple-negative breast
cancer: A brief review about epidemiology, risk factors, signaling
pathways, treatment and role of artificial intelligence. Front Mol
Biosci. 9:8364172022. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wu Q, Siddharth S and Sharma D: Triple
negative breast cancer: A mountain yet to be scaled despite the
triumphs. Cancers (Basel). 13:36972021. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Michaels E, Chen N and Nanda R: The role
of immunotherapy in triple-negative breast cancer (TNBC). Clin
Breast Cancer. 24:263–270. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yin L, Duan JJ, Bian XW and Yu SC:
Triple-negative breast cancer molecular subtyping and treatment
progress. Breast Cancer Res. 22:612020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Deepak KGK, Vempati R, Nagaraju GP, Dasari
VR, S N, Rao DN and Malla RR: Tumor microenvironment: Challenges
and opportunities in targeting metastasis of triple negative breast
cancer. Pharmacol Res. 153:1046832020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Obidiro O, Battogtokh G and Akala EO:
Triple negative breast cancer treatment options and limitations:
Future outlook. Pharmaceutics. 15:17962023. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lehmann BD, Bauer JA, Chen X, Sanders ME,
Chakravarthy AB, Shyr Y and Pietenpol JA: Identification of human
triple-negative breast cancer subtypes and preclinical models for
selection of targeted therapies. J Clin Invest. 121:2750–2767.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ensenyat-Mendez M, Llinàs-Arias P, Orozco
JIJ, Íñiguez-Muñoz S, Salomon MP, Sesé B, DiNome ML and Marzese DM:
Current triple-negative breast cancer subtypes: Dissecting the most
aggressive form of breast cancer. Front Oncol. 11:6814762021.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Won K and Spruck C: Triple-negative breast
cancer therapy: Current and future perspectives (review). Int J
Oncol. 57:1245–1261. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ferrari P, Scatena C, Ghilli M, Bargagna
I, Lorenzini G and Nicolini A: Molecular mechanisms, biomarkers and
emerging therapies for chemotherapy resistant TNBC. Int J Mol Sci.
23:16652022. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Vagia E, Mahalingam D and Cristofanilli M:
The landscape of targeted therapies in TNBC. Cancers (Basel).
12:9162020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hu Y, Wang C, Liang H, Li J and Yang Q:
The treatment landscape of triple-negative breast cancer. Med
Oncol. 41:2362024. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chapdelaine AG and Sun G: Challenges and
opportunities in developing targeted therapies for triple negative
breast cancer. Biomolecules. 13:12072023. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Emara HM, Allam NK and Youness RA: A
comprehensive review on targeted therapies for triple negative
breast cancer: An evidence-based treatment guideline. Discov Oncol.
16:5472025. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Laing K and Secombes CJ: Chemokines. Dev
Comp Immunol. 28:443–460. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nagarsheth N, Wicha MS and Zou W:
Chemokines in the cancer microenvironment and their relevance in
cancer immunotherapy. Nat Rev Immunol. 17:559–572. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Belperio JA, Keane MP, Arenberg DA,
Addison CL, Ehlert JE, Burdick MD and Strieter RM: CXC chemokines
in angiogenesis. J Leukoc Biol. 68:1–8. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Masrour M, Moeinafshar A, Poopak A, Razi S
and Rezaei N: The role of CXC chemokines and receptors in breast
cancer. Clin Exp Med. 25:1282025. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Korbecki J, Bosiacki M, Barczak K, Łagocka
R, Chlubek D and Baranowska-Bosiacka I: The clinical significance
and role of CXCL1 chemokine in gastrointestinal cancers. Cells.
12:14062023. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Łukaszewicz-Zając M, Pączek S, Mroczko P
and Kulczyńska-Przybik A: The significance of CXCL1 and CXCL8 as
well as their specific receptors in colorectal cancer. Cancer Manag
Res. 12:8435–8443. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Korbecki J, Barczak K, Gutowska I, Chlubek
D and Baranowska-Bosiacka I: CXCL1: Gene, promoter, regulation of
expression, mRNA stability, regulation of activity in the
intercellular space. Int J Mol Sci. 23:7922022. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Loetscher P, Seitz M, Clark-Lewis I,
Baggiolini M and Moser B: Both interleukin-8 receptors
independently mediate chemotaxis. Jurkat cells transfected with
IL-8R1 or IL-8R2 migrate in response to IL-8, GRO alpha and NAP-2.
FEBS Lett. 341:187–192. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Talukdar J, Nayek A, Gogoi G, Srivastava
TP, Goel I, Sahoo OS, Dhar R and Karmakar S: Investigating the
interaction of ACKR1 and c-Myc in the breast carcinoma tumor
microenvironment modulation. Discov Oncol. 16:16152025. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Korbecki J, Bosiacki M, Barczak K, Łagocka
R, Brodowska A, Chlubek D and Baranowska-Bosiacka I: Involvement in
tumorigenesis and clinical significance of CXCL1 in reproductive
cancers: Breast cancer, cervical cancer, endometrial cancer,
ovarian cancer and prostate cancer. Int J Mol Sci. 24:72622023.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Korbecki J, Bosiacki M, Pilarczyk M, Kot
M, Defort P, Walaszek I, Chlubek D and Baranowska-Bosiacka I: The
CXCL1-CXCR2 axis as a component of therapy resistance, a source of
side effects in cancer treatment, and a therapeutic target. Cancers
(Basel). 17:16742025. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ullah A, Singla RK, Cao D, Chen B and Shen
B: Age-related and postmenopausal breast cancer progression and
treatment management: The significance of pro-inflammatory
cytokines and CXC chemokines. Genes Dis. 12:1016062025. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Guo L, Hong SC, Wang X, Wang SQ, Wang N,
Wei XQ, Situ HL and Wang ZY: Modulatory effects of XIAOPI formula
on CXCL1 and selected outcomes in triple-negative breast cancer: A
randomized controlled clinical trial. Breast Cancer (Dove Med
Press). 16:289–303. 2024.PubMed/NCBI
|
|
30
|
Wang S, Li J, Hong S, Wang N, Xu S, Yang
B, Zheng Y, Zhang J, Pan B, Hu Y and Wang Z: Chemotherapy-elicited
extracellular vesicle CXCL1 from dying cells promotes
triple-negative breast cancer metastasis by activating TAM/PD-L1
signaling. J Exp Clin Cancer Res. 43:1212024. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang S, Xu S, Li J, Wang N, Zheng Y and
Wang Z: XIAOPI formula inhibits chemoresistance and metastasis of
triple-negative breast cancer by suppressing extracellular
vesicle/CXCL1-induced TAM/PD-L1 signaling. Phytomedicine.
135:1560392024. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zou A, Lambert D, Yeh H, Yasukawa K,
Behbod F, Fan F and Cheng N: Elevated CXCL1 expression in breast
cancer stroma predicts poor prognosis and is inversely associated
with expression of TGF-β signaling proteins. BMC Cancer.
14:7812014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
SenGupta S, Hein LE, Xu Y, Zhang J,
Konwerski JR, Li Y, Johnson C, Cai D, Smith JL and Parent CA:
Triple-negative breast cancer cells recruit neutrophils by
secreting TGF-β and CXCR2 ligands. Front Immunol. 12:6599962021.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yang C, Yu H, Chen R, Tao K, Jian L, Peng
M, Li X, Liu M and Liu S: CXCL1 stimulates migration and invasion
in ER-negative breast cancer cells via activation of the ERK/MMP2/9
signaling axis. Int J Oncol. 55:684–696. 2019.PubMed/NCBI
|
|
35
|
Ciummo SL, D'Antonio L, Sorrentino C,
Fieni C, Lanuti P, Stassi G, Todaro M and Di Carlo E: The C-X-C
motif chemokine ligand 1 sustains breast cancer stem cell
self-renewal and promotes tumor progression and immune escape
programs. Front Cell Dev Biol. 9:6892862021. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Bhat K, Sarkissyan M, Wu Y and Vadgama JV:
GROα overexpression drives cell migration and invasion in triple
negative breast cancer cells. Oncol Rep. 38:21–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Boissière-Michot F, Jacot W, Fraisse J,
Gourgou S, Timaxian C and Lazennec G: Prognostic value of CXCR2 in
breast cancer. Cancers (Basel). 12:20762020. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ignacio RMC, Gibbs CR, Lee ES and Son DS:
The TGFα-EGFR-Akt signaling axis plays a role in enhancing
proinflammatory chemokines in triple-negative breast cancer cells.
Oncotarget. 9:29286–29303. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wang N, Liu W, Zheng Y, Wang S, Yang B, Li
M, Song J, Zhang F, Zhang X, Wang Q and Wang Z: CXCL1 derived from
tumor-associated macrophages promotes breast cancer metastasis via
activating NF-κB/SOX4 signaling. Cell Death Dis. 9:8802018.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Prat A, Pineda E, Adamo B, Galván P,
Fernández A, Gaba L, Díez M, Viladot M, Arance A and Muñoz M:
Clinical implications of the intrinsic molecular subtypes of breast
cancer. Breast. 24 (Suppl):S26–S35. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Acharyya S, Oskarsson T, Vanharanta S,
Malladi S, Kim J, Morris PG, Manova-Todorova K, Leversha M, Hogg N,
Seshan VE, et al: A CXCL1 paracrine network links cancer
chemoresistance and metastasis. Cell. 150:165–178. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wang YY, Chen HD, Lo S, Chen YK, Huang YC,
Hu SCS, Hsieh YC, Hung AC, Hou MF and Yuan SF: Visfatin enhances
breast cancer progression through CXCL1 induction in
tumor-associated macrophages. Cancers (Basel). 12:35262020.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Yuan M, Zhu H, Xu J, Zheng Y, Cao X and
Liu Q: Tumor-derived CXCL1 promotes lung cancer growth via
recruitment of tumor-associated neutrophils. J Immunol Res.
2016:65304102016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Jin K, Pandey NB and Popel AS: Crosstalk
between stromal components and tumor cells of TNBC via secreted
factors enhances tumor growth and metastasis. Oncotarget.
8:60210–60222. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Jeong Y, Yoon SY, Jung SP, Nam SJ, Lee JE
and Kim S: Inhibition of interleukin-8/C-X-C chemokine receptor 2
signaling axis prevents tumor growth and metastasis in
triple-negative breast cancer cells. Pharmacology. 110:178–190.
2025. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Bièche I, Chavey C, Andrieu C, Busson M,
Vacher S, Le Corre L, Guinebretière JM, Burlinchon S, Lidereau R
and Lazennec G: CXC chemokines located in the 4q21 region are
up-regulated in breast cancer. Endocr Relat Cancer. 14:1039–1052.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Dalmases A, González I, Menendez S, Arpí
O, Corominas JM, Servitja S, Tusquets I, Chamizo C, Rincón R,
Espinosa L, et al: Deficiency in p53 is required for doxorubicin
induced transcriptional activation of NF-кB target genes in human
breast cancer. Oncotarget. 5:196–210. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Yang B, Li G, Wang S, Zheng Y, Zhang J,
Pan B, Wang N and Wang Z: Tumor-associated macrophages/C-X-C motif
chemokine ligand 1 promotes breast cancer autophagy-mediated
chemoresistance via IGF1R/STAT3/HMGB1 signaling. Cell Death Dis.
15:7432024. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Zhang L, Gu S, Wang L, Zhao L, Li T, Zhao
X and Zhang L: M2 macrophages promote PD-L1 expression in
triple-negative breast cancer via secreting CXCL1. Pathol Res
Pract. 260:1554582024. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Zheng Y, Wang N, Wang S, Zhang J, Yang B
and Wang Z: Chronic psychological stress promotes breast cancer
pre-metastatic niche formation by mobilizing splenic MDSCs via
TAM/CXCL1 signaling. J Exp Clin Cancer Res. 42:1292023. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Ganguly D, Chandra R, Karalis J, Teke M,
Aguilera T, Maddipati R, Wachsmann MB, Ghersi D, Siravegna G, Zeh
HJ III, et al: Cancer-associated fibroblasts: Versatile players in
the tumor microenvironment. Cancers (Basel). 12:26522020.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Brogna MR, Varone V, DelSesto M and
Ferrara G: The role of CAFs in therapeutic resistance in triple
negative breast cancer: An emerging challenge. Front Mol Biosci.
12:15688652025. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Zhang X, Powell K and Li L: Breast cancer
stem cells: Biomarkers, identification and isolation methods,
regulating mechanisms, cellular origin, and beyond. Cancers
(Basel). 12:37652020. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Olsson M, Larsson P, Johansson J, Sah VR
and Parris TZ: Cancer stem cells are prevalent in the basal-like 2
and mesenchymal triple-negative breast cancer subtypes in vitro.
Front Cell Dev Biol. 11:12376732023. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Burke SJ, Lu D, Sparer TE, Masi T, Goff
MR, Karlstad MD and Collier JJ: NF-κB and STAT1 control CXCL1 and
CXCL2 gene transcription. Am J Physiol Endocrinol Metab.
306:E131–E149. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Punj V, Matta H, Schamus S, Yang T, Chang
Y and Chaudhary PM: Induction of CCL20 production by Kaposi
sarcoma-associated herpesvirus: role of viral FLICE inhibitory
protein K13-induced NF-kappaB activation. Blood. 113:5660–5668.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Richmond A: Nf-kappa B, chemokine gene
transcription and tumour growth. Nat Rev Immunol. 2:664–674. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Han B, Alonso-Valenteen F, Wang Z, Deng N,
Lee TY, Gao B, Zhang Y, Xu Y, Zhang X, Billet S, et al: A chemokine
regulatory loop induces cholesterol synthesis in lung-colonizing
triple-negative breast cancer cells to fuel metastatic growth. Mol
Ther. 30:672–687. 2002. View Article : Google Scholar
|
|
59
|
Mendonca P, Alghamdi S, Messeha S and
Soliman KFA: Pentagalloyl glucose inhibits TNF-α-activated
CXCL1/GRO-α expression and induces apoptosis-related genes in
triple-negative breast cancer cells. Sci Rep. 11:56492021.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Wang J, Ray PS, Sim MS, Zhou XZ, Lu KP,
Lee AV, Lin X, Bagaria SP, Giuliano AE and Cui X: FOXC1 regulates
the functions of human basal-like breast cancer cells by activating
NF-κB signaling. Oncogene. 31:4798–4802. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Wang W, Nag S and Zhang R: Targeting the
NFκB signaling pathways for breast cancer prevention and therapy.
Curr Med Chem. 22:264–289. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Hata K, Andoh A, Shimada M, Fujino S,
Bamba S, Araki Y, Okuno T, Fujiyama Y and Bamba T: IL-17 stimulates
inflammatory responses via NF-kappaB and MAP kinase pathways in
human colonic myofibroblasts. Am J Physiol Gastrointest Liver
Physiol. 282:G1035–G1044. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Sønder SU, Saret S, Tang W, Sturdevant DE,
Porcella SF and Siebenlist U: IL-17-induced NF-kappaB activation
via CIKS/Act1: Physiologic significance and signaling mechanisms. J
Biol Chem. 286:12881–12890. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Khalid F, Takagi K, Sato A, Yamaguchi M,
Guestini F, Miki Y, Miyashita M, Hirakawa H, Ohi Y, Rai Y, et al:
Interleukin (IL)-17A in triple-negative breast cancer: A potent
prognostic factor associated with intratumoral neutrophil
infiltration. Breast Cancer. 30:748–757. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Ma K, Yang L, Shen R, Kong B, Chen W,
Liang J, Tang G and Zhang B: Th17 cells regulate the production of
CXCL1 in breast cancer. Int Immunopharmacol. 56:320–329. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Liu J, Wang P, Huang B, Cheng Q, Duan Y,
Chen L, Ma T, Zhu C, Li D, Fan W and Yu M: Effective suppression of
triple negative breast cancer by paclitaxel nanoparticles
conjugated with transmembrane TNF-α monoclonal antibody. Int J
Pharm. 624:1219692022. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Sharma B, Nawandar DM, Nannuru KC, Varney
ML and Singh RK: Targeting CXCR2 enhances chemotherapeutic
response, inhibits mammary tumor growth, angiogenesis, and lung
metastasis. Mol Cancer Ther. 12:799–808. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Bernard S, Myers M, Fang WB, Zinda B,
Smart C, Lambert D, Zou A, Fan F and Cheng N: CXCL1 derived from
mammary fibroblasts promotes progression of mammary lesions to
invasive carcinoma through CXCR2 dependent mechanisms. J Mammary
Gland Biol Neoplasia. 23:249–267. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Ruiz De Porras V, Bystrup S,
Martínez-Cardús A, Pluvinet R, Sumoy L, Howells L, James MI, Iwuji
C, Manzano JL, Layos L, et al: Curcumin mediates
oxaliplatin-acquired resistance reversion in colorectal cancer cell
lines through modulation of CXC-Chemokine/NF-κB signalling pathway.
Sci Rep. 6:246752016. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Han D, Zhang N, Zhao S, Liu H, Wang X,
Yang M, Wang S, Li Y, Liu Z and Teng L: AKIP1 promotes glioblastoma
viability, mobility and chemoradiation resistance via regulating
CXCL1 and CXCL8 mediated NF-κB and AKT pathways. Am J Cancer Res.
11:1185–1205. 2021.PubMed/NCBI
|
|
71
|
Han XL, Du J, Zheng YD, Dai JJ, Lin SW,
Zhang BY, Zhong FB, Lin ZG, Jiang SQ, Wei W and Fang ZY: CXCL1
clone evolution induced by the HDAC inhibitor belinostat might be a
favorable prognostic indicator in triple-negative breast cancer.
Biomed Res Int. 2021:50893712021. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Park SY, Jun JA, Jeong KJ, Heo HJ, Sohn
JS, Lee HY, Park CG and Kang J: Histone deacetylases 1, 6 and 8 are
critical for invasion in breast cancer. Oncol Rep. 25:1677–1681.
2011.PubMed/NCBI
|
|
73
|
Gibson JT, Orlandella RM, Turbitt WJ,
Behring M, Manne U, Sorge RE and Norian LA: Obesity-associated
myeloid-derived suppressor cells promote apoptosis of
tumor-infiltrating CD8 T cells and immunotherapy resistance in
breast cancer. Front Immunol. 11:5907942020. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Wang Y, Tu L, Du C, Xie X, Liu Y, Wang J,
Li Z, Jiang M, Cao D, Yan X and Luo F: CXCR2 is a novel cancer
stem-like cell marker for triple-negative breast cancer.
OncoTargets Ther. 11:5559–5567. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Li J, Wang S, Wang N, Zheng Y, Yang B,
Wang X, Zhang J, Pan B and Wang Z: Aiduqing formula inhibits breast
cancer metastasis by suppressing TAM/CXCL1-induced Treg
differentiation and infiltration. Cell Commun Signal. 19:892021.
View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Divella R, Daniele A, Savino E, Palma F,
Bellizzi A, Giotta F, Simone G, Lioce M, Quaranta M, Paradiso A and
Mazzocca A: Circulating levels of transforming growth factor-βeta
(TGF-β) and chemokine (C-X-C motif) ligand-1 (CXCL1) as predictors
of distant seeding of circulating tumor cells in patients with
metastatic breast cancer. Anticancer Res. 33:1491–1497.
2013.PubMed/NCBI
|
|
77
|
Zheng Y, Wang N, Wang S, Yang B, Situ H,
Zhong L, Lin Y and Wang Z: XIAOPI formula inhibits the
pre-metastatic niche formation in breast cancer via suppressing
TAMs/CXCL1 signaling. Cell Commun Signal. 18:482020. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Soto-Perez-de-Celis E, Chavarri-Guerra Y,
Leon-Rodriguez E and Gamboa-Dominguez A: Tumor-associated
neutrophils in breast cancer subtypes. Asian Pac J Cancer Prev.
18:2689–2693. 2017.PubMed/NCBI
|
|
79
|
Fridlender ZG, Sun J, Kim S, Kapoor V,
Cheng G, Ling L, Worthen GS and Albelda SM: Polarization of
tumor-associated neutrophil phenotype by TGF-beta: ‘N1’ versus ‘N2’
TAN. Cancer Cell. 16:183–194. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Kang W, Wang C, Wang M, Liu M, Hu W, Liang
X, Yang J and Zhang Y: A key regulator of tumor-associated
neutrophils: The CXCR2 chemokine receptor. J Mol Histol.
55:1051–1061. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Ohms M, Möller S and Laskay T: An attempt
to polarize human neutrophils toward N1 and N2 phenotypes in vitro.
Front Immunol. 11:5322020. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Kythreotou A, Siddique A, Mauri FA, Bower
M and Pinato DJ: PD-L1. J Clin Pathol. 71:189–194. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Clancy JW and D'Souza-Schorey C:
Tumor-derived extracellular vesicles: Multifunctional entities in
the tumor microenvironment. Annu Rev Pathol. 18:205–229. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Wang S, Li J, Xu S, Wang N, Pan B, Yang B,
Zheng Y, Zhang J, Peng F, Peng C and Wang Z: Baohuoside I
chemosensitises breast cancer to paclitaxel by suppressing
extracellular vesicle/CXCL1 signal released from apoptotic cells. J
Extracell Vesicles. 13:e124932024. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Ghallab AM, Eissa RA and El Tayebi HM:
CXCR2 small-molecule antagonist combats chemoresistance and
enhances immunotherapy in triple-negative breast cancer. Front
Pharmacol. 13:8621252022. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Chu H, Li W and Li H: C-X-C motif
chemokine receptor type 2 correlates with higher disease stages and
predicts worse prognosis, and its downregulation enhances
chemotherapy sensitivity in triple-negative breast cancer. Transl
Cancer Res. 9:840–848. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Goldstein LJ, Mansutti M, Levy C, Chang
JC, Henry S, Fernandez-Perez I, Prausovà J, Staroslawska E, Viale
G, Butler B, et al: A randomized, placebo-controlled phase 2 study
of paclitaxel in combination with reparixin compared to paclitaxel
alone as front-line therapy for metastatic triple-negative breast
cancer (fRida). Breast Cancer Res Treat. 190:265–275. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Boissière-Michot F, Jacot W, Massol O,
Mollevi C and Lazennec G: CXCR2 levels correlate with immune
infiltration and a better prognosis of triple-negative breast
cancers. Cancers (Basel). 13:23282021. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Erin N, Tavşan E, Akdeniz Ö, Isca VMS and
Rijo P: Rebound increases in chemokines by CXCR2 antagonist in
breast cancer can be prevented by PKCδ and PKCε activators.
Cytokine. 142:1554982021. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Jaillon S, Ponzetta A, Di Mitri D, Santoni
A, Bonecchi R and Mantovani A: Neutrophil diversity and plasticity
in tumour progression and therapy. Nat Rev Cancer. 20:485–503.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
SenGupta S, Hein LE and Parent CA: The
recruitment of neutrophils to the tumor microenvironment is
regulated by multiple mediators. Front Immunol. 12:7341882021.
View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Xue MQ, Liu J, Sang JF, Su L and Yao YZ:
Expression characteristic of CXCR1 in different breast tissues and
the relevance between its expression and efficacy of neo-adjuvant
chemotherapy in breast cancer. Oncotarget. 8:48930–48937. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Ginestier C, Liu S, Diebel ME, Korkaya H,
Luo M, Brown M, Wicinski J, Cabaud O, Charafe-Jauffret E, Birnbaum
D, et al: CXCR1 blockade selectively targets human breast cancer
stem cells in vitro and in xenografts. J Clin Invest. 120:485–497.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Kwak JW, Nguyen HQ, Camai A, Huffman GM,
Mekvanich S, Kenney NN, Zhu X, Randolph TW and Houghton AM: CXCR1/2
antagonism inhibits neutrophil function and not recruitment in
cancer. OncoImmunology. 13:23846742024. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Miyake M, Furuya H, Onishi S, Hokutan K,
Anai S, Chan O, Shi S, Fujimoto K, Goodison S, Cai W and Rosser CJ:
Monoclonal antibody against CXCL1 (HL2401) as a novel agent in
suppressing IL6 expression and tumoral growth. Theranostics.
9:853–867. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Wang N, Yang B, Zhang J, Zheng Y, Wang S,
Zhang X, Situ H, Lin Y and Wang Z: Metabolite profiling of
traditional Chinese medicine XIAOPI formula: An integrated strategy
based on UPLC-Q-Orbitrap MS combined with network pharmacology
analysis. Biomed Pharmacother. 121:1095692020. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Wang S, Liu X, Huang R, Zheng Y, Wang N,
Yang B, Situ H, Lin Y and Wang Z: XIAOPI formula inhibits breast
cancer stem cells via suppressing tumor-associated
macrophages/C-X-C motif chemokine ligand 1 pathway. Front
Pharmacol. 10:13712019. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Wang S, Wang N, Huang X, Yang B, Zheng Y,
Zhang J, Wang X, Lin Y and Wang Z: Baohuoside i suppresses breast
cancer metastasis by downregulating the tumor-associated
macrophages/C-X-C motif chemokine ligand 1 pathway. Phytomedicine.
78:1533312020. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Wang N, Yang B, Muhetaer G, Wang S, Zheng
Y, Lu J, Li M, Zhang F, Situ H, Lin Y and Wang Z: XIAOPI formula
promotes breast cancer chemosensitivity via inhibiting
CXCL1/HMGB1-mediated autophagy. Biomed Pharmacother.
120:1095192019. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Zhang J, Li L, Kim SH, Hagerman AE and Lü
J: Anti-cancer, anti-diabetic and other pharmacologic and
biological activities of penta-galloyl-glucose. Pharm Res.
26:2066–2080. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Wang P, Song D, Wan D, Li L, Mei W, Li X,
Han L, Zhu X, Yang L, Cai Y and Zhang R: Ginsenoside panaxatriol
reverses TNBC paclitaxel resistance by inhibiting the IRAK1/NF-κB
and ERK pathways. PeerJ. 8:e92812020. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Wang B, Bai S, Wang J, Ren N, Xie R, Cheng
G and Yu Y: TPCA-1 negatively regulates inflammation mediated by
NF-κB pathway in mouse chronic periodontitis model. Mol Oral
Microbiol. 36:192–201. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Seto-Tetsuo F, Arioka M, Miura K, Inoue T,
Igawa K, Tomooka K and Sasaguri T: DIF-1 exhibits anticancer
activity in breast cancer via inhibition of CXCLs/CXCR2
axis-mediated communication between cancer-associated fibroblasts
and cancer cells. Int Immunopharmacol. 117:1099132023. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Palomino DCT and Marti LC: Chemokines and
immunity. Einstein (Sao Paulo). 13:469–473. 2015.(In English,
Portuguese). View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Mehraj U, Mushtaq U, Mir MA, Saleem A,
Macha MA, Lone MN, Hamid A, Zargar MA, Ahmad SM and Wani NA:
Chemokines in triple-negative breast cancer heterogeneity: New
challenges for clinical implications. Semin Cancer Biol.
86:769–783. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Liubomirski Y, Lerrer S, Meshel T,
Rubinstein-Achiasaf L, Morein D, Wiemann S, Körner C and Ben-Baruch
A: Tumor-stroma-inflammation networks promote pro-metastatic
chemokines and aggressiveness characteristics in triple-negative
breast cancer. Front Immunol. 10:7572019. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Liubomirski Y, Lerrer S, Meshel T, Morein
D, Rubinstein-Achiasaf L, Sprinzak D, Wiemann S, Körner C, Ehrlich
M and Ben-Baruch A: Notch-mediated tumor-stroma-inflammation
networks promote invasive properties and CXCL8 expression in
triple-negative breast cancer. Front Immunol. 10:8042019.
View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Brandolini L, Cristiano L, Fidoamore A, De
Pizzol M, Di Giacomo E, Florio TM, Confalone G, Galante A, Cinque
B, Benedetti E, et al: Targeting CXCR1 on breast cancer stem cells:
Signaling pathways and clinical application modelling. Oncotarget.
6:43375–43394. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Toney NJ, Opdenaker LM, Frerichs L,
Modarai SR, Ma A, Archinal H, Ajayi GO and Sims-Mourtada J: B cells
enhance IL-1 beta driven invasiveness in triple negative breast
cancer. Sci Rep. 15:22112025. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Ruan GT, Zhu LC, Xie HL, Zhang HY, Song
MM, Deng L and Shi HP: Adipocyte-derived IL6 and triple-negative
breast cancer cell-derived CXCL1 co-activate STAT3/NF-κB pathway to
mediate the crosstalk between adipocytes and triple-negative breast
cancer cells. Cell Death Discov. 11:3952025. View Article : Google Scholar : PubMed/NCBI
|
